1. Ocugen Inc. (NASDAQ:OCGN)
Ocugen Inc. (NASDAQ:OCGN) is one of the 10 best penny stocks that could triple your money.
On March 24, Ocugen Inc. (NASDAQ:OCGN) announced 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410, its modifier gene therapy for geographic atrophy secondary to dry age-based macular degeneration.
Some key findings from Phase 2 have included a 31% reduction in lesion growth in the optimal dose group compared with the control group. They also incorporated a 27% slower rate of ellipsoid zone loss compared to control, indicating a preservation of structure within the retina, and a 55% response rate for patients treated with OCU410, with a reduction in lesion size of 30% compared to control.
The Phase 2 clinical trial follows on from the clean safety data observed in Phase 1, with no serious adverse events related to OCU410 observed and with no endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy observed to date. Ocugen aims to start the OCU410 Phase 3 registrational trial in the third quarter of 2026, in line with the company’s ambition to submit three BLA filings in three years.
On March 11, Lucid Capital analyst Elemer Piros increased the firm’s price target on Ocugen Inc. (NASDAQ:OCGN) from $15 to $22, while maintaining his Buy rating on the shares. The move follows the company’s announcement of positive preliminary Phase 2 data for its OCU410 therapy, supporting growing confidence in its potential in treating geographic atrophy.
Ocugen Inc. (NASDAQ:OCGN) works on vaccines, biologics, and novel gene and cell therapies that enhance patients’ health. Its product portfolio includes various products, including OCU400 under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of Leber congenital amaurosis, OCU410 and OCU410ST both in Phase 1/2, OCU200 and NeoCart OCU500, OCU510, and OCU520.
While we acknowledge the potential of OCGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OCGN and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
